Antiandrogens

Clascoterone Phase 3 Data Is In, And It's More Complicated Than the Headlines Suggest

The first topical antiandrogen to complete Phase 3 for androgenetic alopecia showed meaningful hair density improvements, but the effect size tells a more nuanced story than its proponents acknowledge.